Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pamrevlumab + Gemcitabine + Nab-paclitaxel in Locally Advanced Pancreatic Cancer
NCT02210559Phase 2Completed
- Sponsor
- FibroGen
- Start
- Jul 2014
- Primary completion
- Dec 2021
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of pamrevlumab in pancreatic ductal adenocarcinoma (PDAC), sponsored by FibroGen. Started Jul 2014; status: completed.
02
Drugs
pamrevlumab
03
Conditions
pancreatic ductal adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT02210559.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02210559.